The role of messenger (m) RNA vaccines in the outbreak of severe acute respiratory syndrome-related coronavirus (SARS-CoV-2) has been very significant.It is necessary to consider whether there are any mRNA-specific aspects to be taken into account regarding the vaccines' efficacy and safety, as well as the design and quality control of mRNA, with an eye toward the development of mRNA vaccines for infectious diseases other than SARS-CoV-2.This review discusses regulatory requirements for assessing the quality, efficacy, and safety of developing mRNA vaccines.
No takes yet. Share an insight, caveat, or question.
Yamaguchi et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: